Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (opens new window)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Źródło‎: Ann Intern Med 2008;148(12):939-55.

Indeks‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (opens new window)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (opens new window)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Źródło‎: Am J Hematol 2000;64(1):26-31.

Indeks‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (opens new window)

Hydroxyurea for the treatment of sickle cell anemia. (opens new window)

Platt OS.

Źródło‎: N Engl J Med 2008;358(13):1362-9.

Indeks‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (opens new window)

Clinical effectiveness of decitabine in severe sickle cell disease. (opens new window)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Źródło‎: Br J Haematol 2008;141(1):126-9.

Indeks‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (opens new window)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (opens new window)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Źródło‎: Blood 2010;115(12):2354-63.

Indeks‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (opens new window)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (opens new window)

Hirst C, Owusu-Ofori S.

Źródło‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indeks‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (opens new window)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (opens new window)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Źródło‎: Lancet Haematol 2021;8(5):e323-33.

Indeks‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (opens new window)

Sickle cell disease. (opens new window)

Meremikwu MM, Okomo U.

Źródło‎: BMJ Clin Evid 2011;02:2402.

Indeks‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (opens new window)

A phase 3 trial of l-glutamine in sickle cell disease. (opens new window)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Źródło‎: N Engl J Med 2018;379(3):226-35.

Indeks‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (opens new window)

Malaria chemoprophylaxis in sickle cell disease. (opens new window)

Oniyangi O, Omari AA.

Źródło‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indeks‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (opens new window)